國藥集團中國生物中部產業基地揭牌 將以疫苗研發生產為核心
國藥集團中國生物武漢生物製品研究所新冠滅活疫苗上市暨中國生物中部產業基地揭牌活動昨日(2月28日)在武漢生物製品研究所舉行。
按照武漢市委市政府與國藥集團中國生物簽署的戰略合作協議內容,將以武漢生物製品研究所為核心,集國藥血製、毓晉生物、國藥動保、國藥基金等板塊,重點圍繞疫苗、血液製品、治療性藥物等方向,開發10個至20個創新產品並實現規模生產,打造以疫苗研發生產為核心的國藥集團中國生物中部產業基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.